- Home
- FLGT vs KOP Comparison
FLGT vs KOP Comparison
Compare FLGT & KOP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLGT
- KOP
- Stock Information
- Founded
- FLGT 2011
- KOP 1988
- Country
- FLGT United States
- KOP United States
- Employees
- FLGT N/A
- KOP N/A
- Industry
- FLGT Medical Specialities
- KOP Forest Products
- Sector
- FLGT Health Care
- KOP Basic Materials
- Exchange
- FLGT Nasdaq
- KOP Nasdaq
- Market Cap
- FLGT 683.5M
- KOP N/A
- IPO Year
- FLGT 2016
- KOP 2006
- Fundamental
- Price
- FLGT $16.37
- KOP $29.53
- Analyst Decision
- FLGT Hold
- KOP Buy
- Analyst Count
- FLGT 1
- KOP 1
- Target Price
- FLGT $22.00
- KOP $64.00
- AVG Volume (30 Days)
- FLGT 226.5K
- KOP 112.3K
- Earning Date
- FLGT 02-26-2025
- KOP 02-26-2025
- Dividend Yield
- FLGT N/A
- KOP 0.95%
- EPS Growth
- FLGT N/A
- KOP N/A
- EPS
- FLGT N/A
- KOP 3.52
- Revenue
- FLGT $277,761,000.00
- KOP $2,128,300,000.00
- Revenue This Year
- FLGT N/A
- KOP N/A
- Revenue Next Year
- FLGT $16.00
- KOP $1.54
- P/E Ratio
- FLGT N/A
- KOP $8.42
- Revenue Growth
- FLGT N/A
- KOP 0.22
- 52 Week Low
- FLGT $16.07
- KOP $28.59
- 52 Week High
- FLGT $26.37
- KOP $58.23
- Technical
- Relative Strength Index (RSI)
- FLGT 34.14
- KOP 36.83
- Support Level
- FLGT $16.68
- KOP $30.13
- Resistance Level
- FLGT $17.27
- KOP $32.01
- Average True Range (ATR)
- FLGT 0.70
- KOP 0.72
- MACD
- FLGT -0.05
- KOP -0.10
- Stochastic Oscillator
- FLGT 13.20
- KOP 24.29
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.